The genetics of sensory gating deficits in schizophrenia

Current Psychiatry Reports

Volumn 5, Issue 2, 2003, Pages 155-161

  Freedman, Robert ^a   Olincy, Ann ^b   Ross, Randall G ^b   Waldo, Merilyne C ^b   Stevens, Karen E ^b   Adler, Lawrence E ^b   Leonard, Sherry ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIMETHOXYBENZYLIDENE ANABASEINE; ALPHA 7 NICOTINIC RECEPTOR; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; NEUROLEPTIC AGENT; NEW DRUG; NICOTINE; NICOTINE GUM; NICOTINIC AGENT; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; 4 AMINOBUTYRIC ACID; ALPHA-BUNGAROTOXIN RECEPTOR; BUNGAROTOXIN RECEPTOR;

ATTENTION; AUDITORY STIMULATION; BIPOLAR DISORDER; BRAIN DYSFUNCTION; CHOLINERGIC STIMULATION; CHROMOSOME 15Q; CLINICAL FEATURE; DRUG ACTIVITY; DRUG DESIGN; DRUG TARGETING; EVOKED AUDITORY RESPONSE; GENE LOCUS; GENETIC LINKAGE; GENETIC POLYMORPHISM; HIPPOCAMPUS; HUMAN; NERVE CELL STIMULATION; NEUROBIOLOGY; NONHUMAN; PATHOPHYSIOLOGY; PROMOTER REGION; REVIEW; SCHIZOPHRENIA; SENSORY DYSFUNCTION; STIMULUS RESPONSE; SYMPTOMATOLOGY; BRAIN; GENETICS; NERVE CELL INHIBITION; PERCEPTION DISORDER; PHYSIOLOGY;

BRAIN; GAMMA-AMINOBUTYRIC ACID; HUMANS; NEURAL INHIBITION; PERCEPTUAL DISORDERS; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); RECEPTORS, NICOTINIC; SCHIZOPHRENIA;

EID: 0142259341     PISSN: 15233812     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11920-003-0032-2     Document Type: Review

References (64)

1. Freedman R, Adler LE, Bickford P, et al.: Schizophrenia and nicotinic receptors. Harv Rev Psychiatry 1994, 2:179-192.
2. Freedman R, Coon H, Myles-Worsley M, et al.: Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc Natl Acad Sci U S A 1997, 94:587-592.
3. Leonard S, Gault J, Hopkins J, et al.: Promoter variants in the a7 nicotinic acetylcholine receptor subunit gene are associated with an inhibitory deficit found in schizophrenia. Arch Gen Psychiatry 2002, In press.
4. Mirnics K, Middleton FA, Stanwood GD, et al.: Disease-specific changes in regulator of G-protein signaling 4 (RGS4) expression in schizophrenia. Mol Psychiatry 2002, 6:293-301.
5. Chumakov I, Blumenfeld M, Guerassimenko O, et al.: Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia. Proc Natl Acad Sci U S A 2002, 99:13675-13680.
6. Egan MF, Goldberg TE, Kolachan BS, et al.: Effect of COMT val 108/158 met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci U S A 2001, 98:6917-6922.
7. Straub R, Jiang Y, MacLean CJ, et al.: Genetic variation in the 6p22.3 gene DTNBP1, the human orthology of the mouse dysbindin gene is associated with schizophrenia. Am J Hum Genet 20002, 7:337-348.
8. Adler LE, Pachtman E, Franks R, et al.: Neurophysiological evidence for a defect in neuronal mechanisms involved in sensory gating in schizophrenia. Biol Psychiatry 1982, 17:639-654.
9. Boutros NN, Zouridakis G, Overall J: Replication and extension of P50 findings in schizophrenia. Clin Electroencephalogr 1991, 22:40-45.
10. Judd LL, McAdams L, Budnick B, Braff DL: Sensory gating deficits in schizophrenia: new results. Am J Psychiatry 1992, 149:488-493.
11. Jin Y, Potkin SG, Patterson JV, et al.: Effects of P50 temporal variability on sensory gating in schizophrenia. Psychiatry Res 1997, 70:71-81.
12. Clementz BA, Geyer MA, Braff DL: P50 suppression among schizophrenia and normal comparison subjects: a methodological analysis. Biol Psychiatry 1997, 41:1035-1044.
13. Yee CM, Nuechterlein KH, Morris SE, White PM: P50 suppression in recent-onset schizophrenia: clinical correlates and risperidone effects. J Abnorm Psychol 1998, 107:691-698.
14. Erwin RJ, Turetskty BI, Gur RE: Dissociation of temporal and spatial P50 subcomponent abnormalities in schizophrenia. Schizophrenia Res 1999, 36:254-261.
15. Ghisolfi ES, Prokopiuk AS, Becker J, et al.: The adenosine antagonist theophylline impairs P50 auditory sensory gating in normal subjects. Neuropsychopharmacology 2002, 26:629-637.
16. Clementz BA, Geyer MA, Braff DL: P50 suppression deficits among the relatives of schizophrenia patients. Schizophr Res 1997, 24:232-241.
17. Cadenhead KS, Light GA, Geyer MA, Braff DL: Sensory gating deficits assessed by the P50 event-related potential in subjects with schizotypal personality disorder. Am J Psychiatry 2000, 157:55-59.
18. Cullum CM, Harris JG, Waldo M, et al.: Neurophysiological and neuropsychological evidence for attentional dysfunction in schizophrenia. Schizophr Res 1993, 10:131-141.
19. Siegel C, Waldo M, Mizner G, et al.: Deficits in sensory gating in schizophrenic patients and their relatives. Arch Gen Psychiatry 1984, 41:607-612.
20. Boutros NN, Gelernter J, Gooding DC, et al.: Sensory gating and psychosis vulnerability in cocaine-dependent individuals: preliminary data. Biol Psychiatry 2002, 51:683-686.
21. Goff WR, Williamson PD, VanGilder JC, et al.: Neural origins of long latency evoked potentials recorded from the depth and from the cortical surface of the brain in man. Prog Clin Neurophysiol 1980, 7:126-145.
22. Benes FM, Berretta S: GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder. Neuropsychopharmacology 2001, 25:1-27.
23. Freedman R, Hall M, Adler LE, Leonard S: Evidence in post-mortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol Psychiatry 1995, 38:22-33.
24. Heckers S: Neuroimaging studies of the hippocampus in schizophrenia. Hippocampus 2001, 11:520-528.
25. Cannon TD, Zorrilla LE, Shtasel D, et al.: Neuropsychological functioning in siblings discordant for schizophrenia and healthy volunteers. Arch Gen Psychiatry 1994, 51:651-661.
26. Suddath RL, Christison GW, Torrey EF, et al.: Anatomical abnormalities in the brains of monozygotic twins discordant for schizophrenia. N Engl J Med 1990, 322:789-794.
27. Seidman LJ, Faraone SV, Goldstein JM, et al.: Left hippocampal volume as a vulnerability indication for schizophrenia: A magnetic resonance imaging morphometric study of non-psychotic first degree relatives. Arch Gen Psychiatry 2002, 59:839-849.
28. Thompson PM, Vidal C, Giedd JN, et al.: Mapping adolescent brain change reveals dynamic wave of accelerated gray matter loss in very early-onset schizophrenia. Proc Natl Acad Sci 2001, 98:11650-11655.
29. Bickford-Wimer PC, Nagamoto H, Johnson R, et al.: Auditory sensory gating in hippocampal neurons: a model system in the rat. Biol Psychiatry 1990, 27:183-192.
30. Luntz-Leybman V, Bickford PC, Freedman R: Cholinergic gating of response to auditory stimuli in rat hippocampus. Brain Res 1992, 587:130-136.
31. Stevens KE, Freedman R, Collins AC, et al.: Genetic correlation of inhibitory gating of hippocampal auditory evoked response and alpha-bungarotoxin-binding nicotinic cholinergic receptors in inbred mouse strains. Neuropsychopharmacology 1996, 15:152-162.
32. Leonard S, Gault J, Moore T, et al.: Further investigation of a chromosome 15 locus in schizophrenia: analysis of affected sibling pairs from the National Institute of Mental Health Genetics Initiative. Am J Med Genet 1998, 81:308-312.
33. Freedman R,. Leonard S, Gault JM, et al.: Linkage dysequilibrium for schizophrenia at the chromosome 15q13-14 locus of the alpha 7-nicotinic acetylcholine receptor subunit gene (CHRNA7). Am J Med Genet 2001, 105:20-22.
34. Freedman R, Leonard S, Olincy A, et al.: Evidence for the multigenic inheritance of schizophrenia. Am J Med Genet 2000, 105: 794-800.
35. Kaufmann CA, Suarez B, Malaspina D, et al.: National Institute of Mental Health Genetics Initiative Millennium Schizophrenia Consortium: linkage analysis of African-American pedigrees. Am J Med Genet 1998, 81:282-289.
36. Gejman PV, Sanders AR, Badner JA, et al.: Linkage analysis of schizophrenia to chromosome 15. Am J Med Genet 2001, 105:789-793.
37. Liu CM, Hwu HG, Lin MW, et al.: Suggestive evidence for linkage of schizophrenia to markers at chromosome 15q13-14 in Taiwanese families. Am J Med Genet 2001, 105:658-661.
38. Riley BP, Makoff AM, Magudi-Carter M, et al.: Haplotype transmission dysequilibrium and evidence for linkage of the CHRNA7 gene region to schizophrenia in Southern African Bantu families. Am J Med Genet 2000, 96:196-201.
39. Stassen HH, Bridler R, Hagele S, et al.: Schizophrenia and smoking: evidence for a common neurobiological basis? Am J Med Genet 2000, 96:173-177.
40. Stöber G, Saar K, Ruschendorf F, et al.: Splitting schizophrenia: periodic catatonia-susceptibility locus on chromosome 15q15. Am J Hum Genet 2000, 67:1201-1207.
41. Tsuang DW Skol AD, Faraone SV, et al.: Examination of genetic linkage of chromosome 15 to schizophrenia in a large veterans affairs cooperative study sample. Am J Med Genet 2001, 105:662-668.
42. Xu J, Pato MT, Torre CD, et al.: Evidence of linkage dysequilibrium between the alpha 7-nicotinic receptor gene (CHRNA7 locus and schizophrenia in Azorean families. Am J Med Genet 2001, 105:669-674.
43. Curtis L, Blouin JL, Radhakrishna U, et al.: Characterization of a series of anabaseine-derived compounds reveals that the 3-4 dimethylaminocinnamylidine derivative is a selective agonist at neuronal nicotinic alpha 7/125I-alpha-bungaro-toxin receptor subtypes. Mol Pharmacol 1995, 47:164-171.
44. DeLisi LE, Shaw SH, Crow TJ, et al.: A genome-wide scan for linkage to chromosomal regions in 382 sibling pairs with schizophrenia or schizoaffective disorder. Am J Psychiatry 2002, 159:803-812.
45. Neves-Pereira M, Bassett AS, Honer WG, et al.: No evidence for linkage of the CHRNA7 gene region in Canadian schizophrenia families. Am J Med Genet 1998, 81:361-363.
46. Turecki G, Grof P, Grof E, et al.: Mapping susceptibility genes for bipolar disorder: a pharmacogenetic approach based on excellent response to lithium. Mol Psychiatry 2001, 6:570-578.
47. Raux G, Bonnet-Brilhault F, Louchart S, et al.: The -2 bp deletion in exon 6 of the "alpha 7-like" nicotinic receptor subunit gene is a risk factor for the P50 sensory gating deficit. Mol Psychiatry 2002, 7:1006-1011.
48. Meyer J, Ortega G, Schraut K, et al.: Exclusion of the neuronal nicotinic acetylcholine receptor alpha-7 subunit gene as a candidate for catatonic schizophrenia in a large family supporting the chromosome 15q13-22 locus. Mol Psychiatry 2002, 7:220-223.
49. Leonard S, Freedman R: Recombination in an National Institute of Mental Health Schizophrenia Genetics Initiative family fails to exclude CHRNA7. Mol Psychiatry 2003, In press.
50. Gault J, Robinson M, Berger R, et al.: Genomic organization and partial duplication of the human alpha-7 neuronal nicotinic acetylcholine receptor gene. Genomics 1998, 52:173-185.
51. Riley B, Williamson M, Collier D, et al.: A 3-Mb map of a large segmental duplication overlapping the alpha 7-nicotinic acetylcholine receptor gene (CHRNA7) at human 15q13-q14. Genomics 2002, 79:197-209.
52. Stitzel JA, Farnham DA, Collins AC: Linkage of strain-specific nicotinic receptor alpha(7) subunit restriction fragment length polymorphisms with levels of alpha-bungarotoxin binding in brain. Mol Brain Res 1996, 43:30-40.
53. Court J, Spurden D, Lloyd S, et al.: Neuronal nicotinic receptors in dementia with Lewy bodies and schizophrenia: alpha-bungarotoxin and nicotine binding in the thalamus. J Neurochemistry 1999, 73:1590-1597.
54. Guan ZZ, Zhang X, Blennow K, Nordberg A: Decreased protein level of nicotinic receptor alpha-7 subunit in the frontal cortex from schizophrenic brain. Neuroreport 1999, 10:1779-1782.
55. Marutle A, Zhang X, Court J, et al.: Laminar distribution of nicotinic receptor subtypes in cortical regions in schizophrenia. J Chem Neuroanat 2001, 22:115-126.
56. Griffith J, O'Neill JE, Petty F, et al.: Nicotinic receptor desensitization and sensory gating deficits in schizophrenia. Biol Psychiatry 1998, 44:98-106.
57. George TP, Vessicchio JC, Termine A, et al.: Effects of smoking abstinence on visuospatial working memory function in schizophrenia. Neuropsychopharmacology 2002, 26:75-85.
58. Adler LE, Hoffer LD, Griffith J, et al.: Normalization by nicotine of deficient auditory sensory gating in the relatives of schizophrenics. Biol Psychiatry 1992, 32:607-616.
59. Adler LE, Hoffer LD, Wiser A, Freedman R: Normalization of auditory physiology by cigarette smoking in schizophrenic patients. Am J Psychiatry 1993, 150:1856-1861.
60. Olincy A, Ross RG, Young DA, et al.: Improvement in smooth pursuit eye movements after cigarette smoking in schizophrenic patients. Neuropsychopharmacology 1998, 18:175-185.
61. Sherr J, Myers C, Avila M, et al.: The effects of nicotine on specific eye tracking measures in schizophrenia. Biol Psychiatry 2002, 52:721-728.
62. Nagamoto HT, Adler LE, Hea RA, et al.: Gating of auditory P50 in schizophrenics: unique effects of clozapine. Biol Psychiatry 1996, 40:181-818.
63. Simosky JK, Stevens K, Adler LE, Freedman R: Clozapine improves deficient inhibitory auditory processing in DBA/2 mice via a nicotinic cholinergic mechanism. Psychopharmacology 2002, In press.
64. Simosky JK, Stevens KE, Kem WR, Freedman R: Intragastric DMXB-A, an alpha7 nicotinic agonist, improves deficient sensory inhibition in DBA/2 mice. Biol Psychiatry 2001, 50:493-500.